GleamWall
中文EN

SNTI Senti Biosciences Holdings, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1854270 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY51.2%
Revenue 3-yr CAGR-69.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-67,652.7%
Net margin-58,140.5%
FCF margin—
EBITDA margin-63,736.5%

Returns

ROE—
ROA-106.2%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets133.9%
Debt / equity—
Current ratio0.54x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-19.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$19,000$17,000$16,000$22,000$0$0$0$0
R&D expense$6.07M$7.77M$5.28M$7.76M$10.52M$10.03M$9.28M$7.77M
SG&A expense$6.27M$6.74M$6.23M$5.85M$6.43M$6.77M$7.12M$8.39M
Operating income-$12.32M-$14.49M-$4.62M-$18.64M-$16.95M-$16.80M-$16.40M-$16.17M
Income tax$0$0$0$0$0$0$0$0
Net income-$11.59M-$12.75M-$4.22M-$14.47M-$18.13M-$14.73M-$14.11M-$610,000
EBITDA-$11.67M-$13.82M-$3.93M-$17.74M-$16.04M-$15.88M-$15.47M-$15.23M
EPS (basic)-0.37-0.41-0.14—-0.69-0.56-1.41—
EPS (diluted)-0.37-0.41-0.14—-0.69-0.56-1.41—
Weighted avg. shares (diluted)31.15M31.14M30.97M—26.23M26.08M10.01M—
Balance sheet
Cash & equivalents$5.55M$6.46M$8.94M$16.42M$15.78M$25.11M$37.35M$51.81M
Current assets$9.52M$13.01M$14.79M$23.27M$18.16M$32.52M$45.21M$58.96M
PP&E, net$10.77M$11.43M$12.10M$12.89M$18.69M$19.59M$20.53M$21.29M
Total assets$28.36M$33.10M$38.24M$51.22M$52.69M$68.54M$82.78M$97.84M
Current liabilities$17.59M$15.77M$14.27M$13.97M$12.03M$9.99M$10.73M$13.15M
Total liabilities$37.96M$36.51M$35.68M$45.63M$44.56M$43.89M$44.92M$47.09M
Shareholders' equity-$9.60M-$3.40M$2.56M$5.59M$8.12M$24.65M$37.86M$25.65M
Shares outstanding31.15M31.14M31.14M30.88M26.29M26.16M26.00M4.83M
Cash flow statement
Operating cash flow-$6.73M-$14.25M-$7.48M-$6.88M-$9.45M-$13.07M-$14.05M-$13.50M
Capital expenditure$0——$0$0$196,000$0$11,000
Free cash flow-$6.73M——-$6.88M-$9.45M-$13.27M-$14.05M-$13.52M
Investing cash flow$0$0$114,000$0$0-$184,000$0-$11,000
Financing cash flow$5.82M$9.68M-$118,000$11.04M$124,000$1.01M-$414,000$51.29M
Depreciation & amortization$650,000$667,000$688,000$893,000$904,000$914,000$926,000$937,000
Stock-based compensation$961,000$1.05M$1.31M$1.43M$1.55M$1.53M$1.20M$605,000

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.